A New Way To Tackle Deal Valuations: Infectious Disease As A Case Study
Despite regulatory uncertainty, the growing problem of antibiotic resistance – especially for gram-negative organisms – has forced big drug companies to take renewed interest in novel anti-infectives.
You may also be interested in...
Deal enables biotech to monetize a portion of its ribosome research while maintaining control over larger segments.
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.